Sertaconazole is a new imidazole fungicide introduced for vulvo-vaginal candidiasis. It has an azole group with benzothiophene that inhibits biosynthesis of ergosterol and brings about a massive leak of cytoplasm with consequent fungal cell death. Results: Out of 188 cases, 177 cases were followed-up completely. Sertaconazole group included 66 cases where 35 cure, 20 fail, and 7 recurrent cases. Fluconazole group included 60 cases and had 37 cure, six fail, and 20 recurrence cases. Clotrimazole group included 55 cases and had 32 cure, nine fail and 11 recurrent cases. There were risk factors of fungal vulvo-vaginitis, including frequent micturition and small toilet shower flushing. Conclusion: Sertaconazole had similar effectiveness and less side-effect as compared with Fluconazole and Clotrimazole. It appeared to work well with lowest recurrence.
Since Clotrimazole has been used in vulvovaginal candidiasis (VVC) for decades, fungal resistance against drugs seems to be increasing. It causes more difficulty in treatment, but also affects healthcare expenditure. The incidence of resistance in patients with candidiasis is still high [1, 2] . However, oral Fluconazole and Clotrimazole vaginal tablet have been used as the current standard treatments of VVC [3] .
Recently, a new imidazole fungicide has been introduced for VVC indication, named Sertaconazole [4, 5] . This is an azole group of antifungal with benzothiophene structure similar to tryptophan in fungal plasma membrane, which facilitates the incorporation of Sertaconazole into fungal cells. Inhibition of biosynthesis of ergosterol by inactivating 14-α-demethylase enzyme results in formation of pores, bringing about a massive leak of cytoplasm and adenosine triphosphate (ATP) with consequent cell death. Sertaconazole also exerts a direct toxic effect on the fungal membrane. With the properties of new structure of this imidazole derivative [6, 7] , we may come to the solution for VVC treatment.
Many clinical researches have been conducted on VVC with antifungal agents for the past ten years. However, there are few studies on new antifungal agents. In this study, we made a comparative study of three drugs (Sertaconazole, Fluconazole, and Clotrimazole) in the treatment of VVC in Thailand. The efficacy, safety and tolerability of Sertaconazole were evaluated for comparison with Fluconazole and Clotrimazole in Thai patients.
Subjects and methods:
A computer-randomized comparative study was conducted in VVC patients between August 31, 2004 and January 30, 2006. This study was approved by the Ethics Committee of Faculty of Medicine, Siriraj Hospital.
One hundred and eighty eight patients with age range of 15-50 years were recruited from patients who were treated at Outpatient Gynecologic Department of Siriraj Hospital, Bangkok. We included: 1) patients who are clinically compatible with VVC infection, 2) cases who are confirmed by laboratory examination (direct and/or culture) for Candida species, 3) patients who consented to participate in the study and comply to follow-up and evaluation program, and 4) patients who agreed to discontinue any antifungal agents at least two weeks before enrollment. The following patients were excluded: 1) patients with history of hypersensitivity to azole drugs, 2) pregnancy, 3) patients who did not meet any of the inclusion criteria.
The subjects were computer-randomized in to three groups according to the medication as follows.
Group A (Fluconazole): Patients took oral Fluconazole 150 mg (50 mg x3) single dose [8] , Group B (Clotrimazole): Patients were trained to insert Clotrimazole 100 mg vaginal tablet once a day for six consecutive days at bedtime [9] , Group C (Sertaconazole): Patients were trained to insert single Sertaconazole 500 mg vaginal tablet at bedtime [5] .
Procedures
Confirming that patients were clinically compatible with VVC using microscopic examination and/or culture, we requested them to give their writtenconsent. Data were collected on the case report form. Then, pharmacist randomly dispensed medication with the recorded code. Clinical assessments were recorded at week 1 for efficacy and safety. Mycological examinations were performed [10] . Repeated-assessment was performed at week 4 to evaluate for recurrence. Finally, patients were requested to fill-up the evaluation form at the end of follow-up period.
Mycological assessment and yeast identification
The specimens were collected from the patient's vagina by clinicians on site using sterile cotton swabs. Swabs were transferred in sterile normal saline tubes at room temperature. They were determined for yeast pathogens as follows [11] .
Direct microscopic examination. Swab was directly examined under a microscope with wet preparation smear on glass slide. The morphological characteristics of budding yeast, pseudohyphae, and hyphae were recorded.
Yeast identification. Swabs were directly streaked on Candi Select ® media (Sanofi Diagnostic, Pasteur, Marnes-La-Coquette, France) [12] that is a selective media to promote the growth of yeast and to inhibit bacterial contamination. After incubation at 37°C for 24-48 hours, C. Albicans was identified as blue colony appearance, as recommended by the manufacturer. White colony indicated non-C. Albicans species.
All those, identified presumptively as C. Albicans, were screened for C. Dubliniensis [13, 14] by cultivation on slant of Saboraud Dextrose Agar (SDA) and incubation at 45°C for 48 hours. The isolate that could not grow at this condition, was suspected to be C. dubliniensis. This was further confirmed by polymerase chain reaction (PCR). Yeasts that are negative in C. Albicans testing were identified to species level using urea hydrolysis carbohydrate assimilation and fermentation tests. The isolates were tested with each sugar, such as dextrose, maltose, sucrose, lactose, galactose, trehalose cellobiose, and soluble starch [15] .
All culture positive isolates were tested at their minimum inhibition concentrations (MICs) and minimum fungicidal concentration (MFCs) [5] .
The MIC testing was performed for Sertaconazole, Fluconazole, and Itraconazole [16] , Clotrimazole and Ketoconazole by a broth microdilution method, according to the recommendations of The National Committee for Clinical Laboratory Standards (NCCLS). The testing medium was RPMI (Royal Park Memorial Institute, Thailand) media (pH 7.0).
The MIC was defined as the lowest concentration that reduces growth by 80% relative to that of the growth control. The 80% inhibition endpoint was estimated by diluting the drug-free growth control tube 1:5 with test medium. The MFCs of the drugs was tested by determination of growth ability of the isolates in MIC testing wells after subculture on SDA media, and incubated 37°C for 24-48 hours. The MFC was defined as the lowest concentration to show no yeast growth on the media [17] . This included 55 Clotrimazole, 66 Sertaconazole,and 67 Fluconazole cases.
Results
Out of 188 patients enrolled in the study, 177 patients had completed follow-up for four weeks, while 11 cases were lost to follow-up. For three groups of treatment (Sertaconazole, Fluconazole, and Clotrimazole groups), characteristics and follow-up of patients are summarized in Table 1 and 2, respectively. Table 3 .
Sertaconazole had some difficulty in dissolvation, which might increase the failure rate of medication. This problem could be solved by dipping the drug into clean water for five seconds before vaginal insertion. Then, we evaluated results of treatment for medications by Sertaconazole separately in two cases with partially-undissolved and completelydissolved drugs. Table 4 shows results of treatment for medications by Sertaconazole in fraction, where no.1-66 and no.67-188 might include undissolved drugs and completely-dissolved drugs, respectively.
As risk factors of fungal vulvo-vaginitis, factors of frequent micturition, vulvar cleaning, and associated sexually transmitted diseases were summarized in Table 5 . 
Discussion
The objectives of the present study were to evaluate the antifungal efficacy [18] , recurrent rate and safety and tolerability of three drugs (Clotrimazole, Fluconazole, and Sertaconazole). In the present analysis based on of 188 subjects, these drugs had similar effectiveness in treatment of vulvo-vaginal candidiasis. The rate of cure (or effectiveness) fell in the range of approximately 55%, as shown in Table 3 . However, Sertaconazole had some difficulty in dissolvation, which could be easily expulsed from the patients' vagina. When those subjects with undissolved drugs were excluded, the effectiveness of Sertaconazole was increased up to 58.5% from 53.0%, as shown in Table 4 . This suggests that Sertaconazole might be the most effective medication among the three drugs.
In relation to the recurrent rate, Fluconazole had the highest rate of relapse of 29.9%, and Clotrimazole had consecutively high relapse rate of 20%. On the other hand, Sertaconazole had the lowest relapse rate of only 10.6% (Table 3) . Fluconazole has been used in oral form [19] . It also been used commonly among AIDS patients with fungal opportunistic infection. Clotrimazole is used as a long-term clinical antifungal agent [20] .
In relation to the safety, the present results showed minimal side-effect without adverse event. In clinical practice, Fluconazole has advantage due to oral form, and can be used more easily, compared to Sertaconazole (500 mg) and Clotrimazole (100 mg) in vaginal form [21] . Antifungal vaginal tablet is still favorably used because of the belief that vaginal disease should be treated by vaginal medication. Some Thai females trust the six-day regimen [21] of vaginal tablets more than one-day regimen, although several studies show equal antifungal efficacy between the two regimens. The one-day regimen (500 mg Sertaconazole vaginal tablet) [22] seemed to be less popular than the previous six-day regimen (100 mg Clotrimazole vaginal tablet).
The duration of infection was 7-14 days in most patients. The number of patients with previouslyexperienced fungal vulvo-vaginitis is the same with those who had it for the first time. As shown in Table  1 , most patients never have antibiotics or corticosteroid prior to the infection, and only one-third have oral contraception. In our study, only few patients had history of diabetes mellitus and several cases of low immunity, one case of immune disease, and seven cases of HIV-infection. In addition, more than onethird of our patients wore tight thick clothing, especially jean trousers or pants (see Table 5 ). Vulvar cleansing after urination by toilet shower or simple water-use increased significantly in Thailand. A small number of patients use antiseptic solution or vaginal douching for vulvar cleansing. To analyze recurrent and not-recurrent fungal infection, we selected data on clothing, toilet vulvar cleansing, and frequent micturition from our patients who came back for four-week follow-up. In the present analysis based on 188 subjects, 65 (34.6%) wear tight and thick clothing, especially jean trouser or pant and 123 (65.4%) wear simple clothing. Forty cases use the toilet shower to clean vulva every time after urination while 53 uses it only some of the time. Thus, the calculated rate of toilet shower use is 90 cases (47.9%). Twenty-eight cases use simple water to clean vulva every time after urination while 42 uses it only some of the time. Thus, 37.2% of the patients used simple water. The other 14.9% of the patients may use toilet tissue paper instead of vulvar cleansing. These data might reflect the fact that vulvar moisture would occur due to such uses of either toilet shower or simple water use in toilet.
Fungal vulvo-vaginitis could be transmitted by sexual intercourse. Generally, fungal vulvo-vaginitis is found after treatment of trichomoniasis because of the change of vaginal pH after such treatment. However, most STD might occur separately.
In some immuno-compromised patients [23] such as cases of HIV-positive and lymphoma on chemotherapy, no recurrent case was observed in the study.
In conclusion, Sertaconazole had similar effectiveness and less side-effect with Fluconazole and Clotrimazole. It appeared to work well with lowest recurrence.
